Phase II trial of temsirolimus in patients with relapsed or refractory multiple myeloma

Sherif Farag, Shuhong Zhang, Buffy S. Jansak, Xiaojing Wang, Eric Kraut, Kenneth Chan, Janet E. Dancey, Michael R. Grever

Research output: Contribution to journalArticle

64 Citations (Scopus)

Abstract

In a phase II trial, 16 patients with relapsed refractory multiple myeloma received temsirolimus 25 mg I.V. weekly until progression. One partial response and 5 minor responses were observed for a total response rate of 38%. The median time to progression was 138 days. Grade 3-4 toxicity included fatigue (n = 3), neutropenia (n = 2), thrombocytopenia (n = 2), interstitial pneumonitis (n = 1), stomatitis (n = 1) and diarrhea (n = 1). Clinical activity was associated with a higher area under the curve (AUC) and maximal reduction in phosphorylated p70S6K and 4EBP1 in peripheral blood mononuclear cells. At the dose and schedule used, temsirolimus had low single agent activity. Investigation of alternate dosing schedules and use in combinations is indicated.

Original languageEnglish
Pages (from-to)1475-1480
Number of pages6
JournalLeukemia Research
Volume33
Issue number11
DOIs
StatePublished - Nov 2009

Fingerprint

Multiple Myeloma
Appointments and Schedules
70-kDa Ribosomal Protein S6 Kinases
Stomatitis
Interstitial Lung Diseases
Neutropenia
Area Under Curve
Fatigue
Diarrhea
Blood Cells
temsirolimus
Thrombocytopenia chromosome breakage

Keywords

  • mTOR
  • Multiple myeloma
  • Pharmacokinetics
  • Temsirolimus

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

Farag, S., Zhang, S., Jansak, B. S., Wang, X., Kraut, E., Chan, K., ... Grever, M. R. (2009). Phase II trial of temsirolimus in patients with relapsed or refractory multiple myeloma. Leukemia Research, 33(11), 1475-1480. https://doi.org/10.1016/j.leukres.2009.01.039

Phase II trial of temsirolimus in patients with relapsed or refractory multiple myeloma. / Farag, Sherif; Zhang, Shuhong; Jansak, Buffy S.; Wang, Xiaojing; Kraut, Eric; Chan, Kenneth; Dancey, Janet E.; Grever, Michael R.

In: Leukemia Research, Vol. 33, No. 11, 11.2009, p. 1475-1480.

Research output: Contribution to journalArticle

Farag, S, Zhang, S, Jansak, BS, Wang, X, Kraut, E, Chan, K, Dancey, JE & Grever, MR 2009, 'Phase II trial of temsirolimus in patients with relapsed or refractory multiple myeloma', Leukemia Research, vol. 33, no. 11, pp. 1475-1480. https://doi.org/10.1016/j.leukres.2009.01.039
Farag, Sherif ; Zhang, Shuhong ; Jansak, Buffy S. ; Wang, Xiaojing ; Kraut, Eric ; Chan, Kenneth ; Dancey, Janet E. ; Grever, Michael R. / Phase II trial of temsirolimus in patients with relapsed or refractory multiple myeloma. In: Leukemia Research. 2009 ; Vol. 33, No. 11. pp. 1475-1480.
@article{1f28291c060748b98110c65e2e8d3b71,
title = "Phase II trial of temsirolimus in patients with relapsed or refractory multiple myeloma",
abstract = "In a phase II trial, 16 patients with relapsed refractory multiple myeloma received temsirolimus 25 mg I.V. weekly until progression. One partial response and 5 minor responses were observed for a total response rate of 38{\%}. The median time to progression was 138 days. Grade 3-4 toxicity included fatigue (n = 3), neutropenia (n = 2), thrombocytopenia (n = 2), interstitial pneumonitis (n = 1), stomatitis (n = 1) and diarrhea (n = 1). Clinical activity was associated with a higher area under the curve (AUC) and maximal reduction in phosphorylated p70S6K and 4EBP1 in peripheral blood mononuclear cells. At the dose and schedule used, temsirolimus had low single agent activity. Investigation of alternate dosing schedules and use in combinations is indicated.",
keywords = "mTOR, Multiple myeloma, Pharmacokinetics, Temsirolimus",
author = "Sherif Farag and Shuhong Zhang and Jansak, {Buffy S.} and Xiaojing Wang and Eric Kraut and Kenneth Chan and Dancey, {Janet E.} and Grever, {Michael R.}",
year = "2009",
month = "11",
doi = "10.1016/j.leukres.2009.01.039",
language = "English",
volume = "33",
pages = "1475--1480",
journal = "Leukemia Research",
issn = "0145-2126",
publisher = "Elsevier Limited",
number = "11",

}

TY - JOUR

T1 - Phase II trial of temsirolimus in patients with relapsed or refractory multiple myeloma

AU - Farag, Sherif

AU - Zhang, Shuhong

AU - Jansak, Buffy S.

AU - Wang, Xiaojing

AU - Kraut, Eric

AU - Chan, Kenneth

AU - Dancey, Janet E.

AU - Grever, Michael R.

PY - 2009/11

Y1 - 2009/11

N2 - In a phase II trial, 16 patients with relapsed refractory multiple myeloma received temsirolimus 25 mg I.V. weekly until progression. One partial response and 5 minor responses were observed for a total response rate of 38%. The median time to progression was 138 days. Grade 3-4 toxicity included fatigue (n = 3), neutropenia (n = 2), thrombocytopenia (n = 2), interstitial pneumonitis (n = 1), stomatitis (n = 1) and diarrhea (n = 1). Clinical activity was associated with a higher area under the curve (AUC) and maximal reduction in phosphorylated p70S6K and 4EBP1 in peripheral blood mononuclear cells. At the dose and schedule used, temsirolimus had low single agent activity. Investigation of alternate dosing schedules and use in combinations is indicated.

AB - In a phase II trial, 16 patients with relapsed refractory multiple myeloma received temsirolimus 25 mg I.V. weekly until progression. One partial response and 5 minor responses were observed for a total response rate of 38%. The median time to progression was 138 days. Grade 3-4 toxicity included fatigue (n = 3), neutropenia (n = 2), thrombocytopenia (n = 2), interstitial pneumonitis (n = 1), stomatitis (n = 1) and diarrhea (n = 1). Clinical activity was associated with a higher area under the curve (AUC) and maximal reduction in phosphorylated p70S6K and 4EBP1 in peripheral blood mononuclear cells. At the dose and schedule used, temsirolimus had low single agent activity. Investigation of alternate dosing schedules and use in combinations is indicated.

KW - mTOR

KW - Multiple myeloma

KW - Pharmacokinetics

KW - Temsirolimus

UR - http://www.scopus.com/inward/record.url?scp=68649117850&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=68649117850&partnerID=8YFLogxK

U2 - 10.1016/j.leukres.2009.01.039

DO - 10.1016/j.leukres.2009.01.039

M3 - Article

VL - 33

SP - 1475

EP - 1480

JO - Leukemia Research

JF - Leukemia Research

SN - 0145-2126

IS - 11

ER -